Get the Stockscreener App
1.18
6.31%
0.07
Precigen Inc stock is traded at $1.18, with a volume of 1.62M.
It is up +6.31% in the last 24 hours and up +54.73% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$1.11
Open:
$1.13
24h Volume:
1.62M
Relative Volume:
1.24
Market Cap:
$345.59M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-3.0256
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+8.76%
1M Performance:
+54.73%
6M Performance:
-25.79%
1Y Performance:
-7.81%
1-Day Range:
$1.11
$1.23
1-Week Range:
$1.0701
$1.23
52-Week Range:
$0.6513
$1.93
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
1.18 | 345.59M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Precigen, Inc. Regains Compliance with Nasdaq Listing Rules - Defense World
Precigen shares rebound above Nasdaq minimum bid price - MSN
Precigen shares rebound above Nasdaq minimum bid price By Investing.com - Investing.com Australia
Should You Invest in Precigen (PGEN)? - MSN
Jane Street Group LLC Reduces Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment By Investing.com - Investing.com Australia
Precigen's SWOT analysis: gene therapy stock focuses on RRP treatment - Investing.com India
Precigen's (PGEN) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Precigen to Present Plans for Realizing Commercial Vision for PR - GuruFocus.com
Precigen Files BLA for Breakthrough RRP Treatment PRGN-2012, Targets 27,000 US Patients - StockTitan
Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
Precigen CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Barclays PLC Acquires 124,141 Shares of Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Geode Capital Management LLC - Defense World
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - MSN
Investors Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - Defense World
Traders Purchase High Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat
Exploring 3 Prominent High Growth Tech Stocks In The United States - Simply Wall St
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally - MSN
Precigen, Inc. (NASDAQ:PGEN) Shares Acquired by State Street Corp - Defense World
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail - Asianet Newsable
Stifel Financial Corp Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Precigen's SWOT analysis: gene therapy firm's stock faces pivotal year By Investing.com - Investing.com Australia
Precigen, Inc. announced that it has received $79 million in funding - Marketscreener.com
Precigen’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Precigen's SWOT analysis: gene therapy firm's stock faces pivotal year - Investing.com
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment - Benzinga
Precigen Completes Submission of BLA with Request for Priority R - GuruFocus.com
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis – Company AnnouncementFT.com - Financial Times
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - Defense World
Precigen announces $79 million private placement offering of convertible preferred stock - MSN
Precigen secures $79 million in private placement By Investing.com - Investing.com Canada
Precigen, Inc. Enters into Asset Acquisition Agreement with Innovator 21, LLC - Defense World
Precigen, Inc. announced that it expects to receive $79 million in funding - Marketscreener.com
Precigen Announces $79.0 Million Private Placement Offering of C - GuruFocus.com
Precigen secures $79 million in private placement - Investing.com
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock - Nasdaq
Nnovator 21, LLC acquired Certain assets, including intellectual property rights and royalty rights, related to FCX-007 from Precigen, Inc. for $8.5 million. - Marketscreener.com
Precigen, Inc. (NASDAQ:PGEN) Shares Bought by HighTower Advisors LLC - Defense World
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Analysts Update Their Estimates For Precigen Inc - Stocks Register
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):